294 related articles for article (PubMed ID: 34409732)
21. Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.
Blaj C; Schmidt EM; Lamprecht S; Hermeking H; Jung A; Kirchner T; Horst D
Cancer Res; 2017 Apr; 77(7):1763-1774. PubMed ID: 28202525
[TBL] [Abstract][Full Text] [Related]
22. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
[TBL] [Abstract][Full Text] [Related]
23. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
[TBL] [Abstract][Full Text] [Related]
24. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
25. Serine-threonine Kinase Receptor-Associated Protein is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis Through a Feed-Forward Mechanism.
Vu T; Datta A; Banister C; Jin L; Yuan G; Samuel T; Bae S; Eltoum IE; Manne U; Zhang B; Welner RS; Mitra K; Buckhaults P; Datta PK
Gastroenterology; 2022 Jan; 162(1):193-208. PubMed ID: 34520730
[TBL] [Abstract][Full Text] [Related]
26. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient.
Osumi H; Muroi A; Sakahara M; Kawachi H; Okamoto T; Natsume Y; Yamanaka H; Takano H; Kusama D; Shinozaki E; Ooki A; Yamaguchi K; Ueno M; Takeuchi K; Noda T; Nagayama S; Koshikawa N; Yao R
Sci Rep; 2020 Oct; 10(1):17455. PubMed ID: 33060766
[TBL] [Abstract][Full Text] [Related]
28. Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer.
Gularte-Mérida R; Smith S; Bowman AS; da Cruz Paula A; Chatila W; Bielski CM; Vyas M; Borsu L; Zehir A; Martelotto LG; Shia J; Yaeger R; Fang F; Gardner R; Luo R; Schatz MC; Shen R; Weigelt B; Sánchez-Vega F; Reis-Filho JS; Hechtman JF
JCO Precis Oncol; 2022 Mar; 6():e2100365. PubMed ID: 35235413
[TBL] [Abstract][Full Text] [Related]
29. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
30. Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer.
Dietinger V; García de Durango CR; Wiechmann S; Boos SL; Michl M; Neumann J; Hermeking H; Kuster B; Jung P
Cell Commun Signal; 2020 Jun; 18(1):102. PubMed ID: 32586342
[TBL] [Abstract][Full Text] [Related]
31. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
32. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
33. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Najafi M; Ahmadi A; Mortezaee K
Cell Biol Int; 2019 Nov; 43(11):1206-1222. PubMed ID: 31136035
[TBL] [Abstract][Full Text] [Related]
34. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
35. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
36. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
37. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
38. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H
Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816
[TBL] [Abstract][Full Text] [Related]
39. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
[No Abstract] [Full Text] [Related]
40. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
